ADC Therapeutics shares are trading higher after Guggenheim initiated coverage on the stock with a Buy rating and announced a price target of $11.
Portfolio Pulse from Benzinga Newsdesk
ADC Therapeutics shares surged following Guggenheim's initiation of coverage with a Buy rating and a price target of $11.

March 28, 2024 | 3:32 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
ADC Therapeutics shares experienced a significant increase after Guggenheim initiated coverage with a Buy rating and a price target of $11.
The initiation of coverage by a reputable financial institution like Guggenheim, especially with a Buy rating and a specific price target, typically generates positive investor sentiment. This can lead to increased buying activity, driving up the stock price in the short term.
CONFIDENCE 95
IMPORTANCE 90
RELEVANCE 100